AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy